Pricing In ‘Exceptional’ Times: ICER Aims To Shape US Policy For Novel COVID Drugs, Vaccines

 
• By Cathy Kelly

US Institute for Clinical and Economic Review lays out options ranging from the status quo (unrestricted pricing) to compulsory licensing and advanced market commitments in a new white paper.

Microscopic cells of Coronavirus
Consensus On Payment Models Needed

More from Market Access

More from Pink Sheet